Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study
The three miRNA panels demonstrate substantial diagnostic potential for prostate cancer and are anticipated to help reduce the high false positive and false negative rates commonly seen with PSA testing.
Authors
- Liangchao Ni (ORCID: https://orcid.org/0000-0002-2758-9930)
- Lingzhi Tao (ORCID: https://orcid.org/0000-0001-8560-6228)
- Yongqing Lai
- Siwei Chen (ORCID: https://orcid.org/0000-0001-9115-5996)
- Wenkang Chen (ORCID: https://orcid.org/0000-0001-7326-2595)
- Yingqi Li (ORCID: https://orcid.org/0009-0007-6169-405X)
- Huimei Zhou (ORCID: https://orcid.org/0009-0008-5085-6110)
- Wuping Wang (ORCID: https://orcid.org/0000-0002-6791-2050)
- Zhenjian Ge
- Pengwu Zhang
- Shengjie Lin
- Xutai Li
- Yutong Wu
Institutions
- Anhui Medical University (CN)
- Hong Kong University of Science and Technology (HK)
- Peking University (CN)
- Shantou University (CN)
- Shantou University Medical College (CN)
- Peking University Shenzhen Hospital (CN)
- Shenzhen University Health Science Center (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1080/14796694.2025.2514930
- Citations
- 1
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.94